"Ursodeoxycholic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.
Descriptor ID |
D014580
|
MeSH Number(s) |
D04.210.500.105.225.272.962 D04.210.500.221.430.342.925
|
Concept/Terms |
Ursodeoxycholic Acid- Ursodeoxycholic Acid
- Acid, Ursodeoxycholic
- Ursacholic Acid
- Acid, Ursacholic
- 3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid
- 3 alpha,7 beta Dihydroxy 5 beta cholan 24 oic Acid
- Ursodiol
- Deoxyursocholic Acid
- Acid, Deoxyursocholic
|
Below are MeSH descriptors whose meaning is more general than "Ursodeoxycholic Acid".
Below are MeSH descriptors whose meaning is more specific than "Ursodeoxycholic Acid".
This graph shows the total number of publications written about "Ursodeoxycholic Acid" by people in this website by year, and whether "Ursodeoxycholic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 1 | 1 | 2 |
2012 | 0 | 1 | 1 |
2017 | 3 | 2 | 5 |
2018 | 4 | 3 | 7 |
2019 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Ursodeoxycholic Acid" by people in Profiles.
-
Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm. Med Hypotheses. 2020 10; 143:109897.
-
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. Lancet Gastroenterol Hepatol. 2019 10; 4(10):781-793.
-
Women successfully treated for severe intrahepatic cholestasis of pregnancy do not have increased risks for adverse perinatal outcomes. Medicine (Baltimore). 2019 Jul; 98(27):e16214.
-
Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Lipids Health Dis. 2019 Apr 06; 18(1):88.
-
Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients. Hepatology. 2019 04; 69(4):1648-1656.
-
Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacol Res. 2018 09; 135:144-149.
-
Pancreatic Cystosis and Intrahepatic Biliopathy in a Young Adult with Cystic Fibrosis. J Pediatr. 2018 12; 203:457-457.e1.
-
How best to manage chronic cholestasis. J Fam Pract. 2018 Jul; 67(7):E9-E15.
-
Management of Chronic Hepatic Itch. Dermatol Clin. 2018 Jul; 36(3):293-300.
-
Intrahepatic Cholestasis of Pregnancy: A Review of Diagnosis and Management. Obstet Gynecol Surv. 2018 Feb; 73(2):103-109.